Industry News

Max Financial Services Ltd have cleared a proposal to pay a Rs.850 crore non-compete fee to Analjit Singh and other promoters of the Max group. This was a pre-requisite to the firm's three-way merger with its unit Max Life Insurance Co. Ltd and HDFC Life Insurance Co. Ltd.. Around 65% of votes polled were in favour of the resolution to pay the non-compete fee, said a Max Financial notice to the stock exchanges on Tuesday."/>
HDFC Life-Max merger: Max Financial shareholders okay non-compete fee [Mint, New Delhi]
Karolinska Development AB today announces that its portfolio company Dilafor AB, a drug development company focusing on the development of tafoxiparin for obstetric indications, has successfully completed a financing round raising SEK 51 million from new and existing investors. New investors include Lee's Healthcare Industry Fund, Rosetta Capital IV and Pila AB. Dilafor's largest existing shareholder, KDev Investments (an investment fund..."/>
Karolinska Development portfolio company Dilafor AB raises SEK 51 million to facilitate Phase IIb clinical study with tafoxiparin
Bionor Pharma ASA regarding the primary insider notification from certain primary insiders of the Company that have received Subscription Rights in the Rights Issue."/>
Bionor Pharma ASA : Primary inside Notification - Cecilie Grue
Staples removes interim tag, names Goodman CEO. Staples Inc. named interim Chief Executive Officer Shira Goodman to the position on a permanent basis, betting on a company veteran as the office-supply retailer works to move forward from its failed merger with Office Depot Inc.. Goodman also will join the board, the Framingham-based company said yesterday in a statement."/>
Boston Herald The Ticker column [Boston Herald]
Teva Pharmaceutical Industries Ltd. in the New York court regarding the acquisition of the Mexican firm Rimsa will probably not be the only legal action Teva will have to conduct regarding this acquisition. Yesterday, the Central District Court received a request to file a derivative suit against Teva, company directors and executives, including CEO Erez Vigodman and CFO Eyal Desheh, and against Citigroup, which provided Teva with consultation..."/>
Shareholders sue Teva over Rimsa acquisition [Globes, Tel Aviv, Israel]
Piramal Enterprises Ltd's Structured Finance Group, the non-real estate lending business, plans to provide customized lending solutions to companies across sectors and double its team as it seeks to expand its business aggressively. "Any promoter anywhere in India who wants money, wants flexibility and wants a good partner, should call on us. We want to become the first port of call for all companies, "said Khushru Jijina, managing director at Piramal Fund..."/>
Piramal's SFG plans aggressive expansion [Mint, New Delhi]
CCI approves Sanofi-Boehringer asset swap [Mint, New Delhi]
CEL-SCI Corporation announced today that it has received verbal notice from the U.S. Food and Drug Administration that its Multikine Phase 3 clinical trial in advanced primary head and neck cancer has been placed on clinical hold. Pursuant to this communication from FDA, patients currently receiving study treatments can continue to receive treatment, and patients already enrolled in the study will continue to be followed."/>
CEL-SCI Reports Clinical Hold on Head and Neck Cancer Study
CBOE Holdings Inc.. The deal comes less than four years after Chicago-based CME Group agreed to buy the 156- year-old Kansas City Board of Trade."/>
Lenexa-based Bats Global Markets agrees to $3.2 billion buyout [The Kansas City Star]
UNIFIRST CLOSES USD 122 M ACQUISITION OF ARROW UNIFORM. US-based work uniforms and facility services provider UniFirst Corp. has completed its acquisition of US-based Arrow Uniform for approximately USD 122 m, the company said."/>
M and A Navigator: Deal pipeline –26 September
Rennova Health has a new woe: Its landlord wants $1.94 million in unpaid rent. In a lawsuit filed this week in Palm Beach County, property owner Reflect Co. LLC says Medytox Solutions, as Rennova was known until recently, is in default of its lease after missing an August rent payment on its headquarters at 400 Australian Ave. in West Palm Beach. Rennova, a medical testing firm, has been hemorrhaging money."/>
Best of Our Blogs: Rennova Health owes rent; holiday travel tips [The Palm Beach Post, Fla.]
Intrexon Corporation, a leader in synthetic biology, today announced that pursuant to New York Stock Exchange Rule 303 A.08 it granted Geno J. Germano an employment inducement award in connection with Mr. As Intrexon previously disclosed in a Current Report on Form 8- K filed on May 17, 2016, the Intrexon Compensation Committee approved the award to Mr. Germano of options to purchase an aggregate of 2,000,000 shares of the Company's common..."/>
Intrexon Grants Employment Inducement Award Pursuant to NYSE Rule 303A.08
RepliCel Life Sciences Inc., a clinical-stage regenerative medicine company focused on the development of autologous cell therapies, is pleased to provide an update on the licensing and co-development of its RCH-01 product with Shiseido Company. As announced in July, RepliCel's RCH-01 product, for the treatment of androgenetic alopecia, is now under clinical investigation at Tokyo Medical University Hospital and Toho University..."/>
RepliCel Provides Update on Shiseido License and Co-Development for RCH-01
UnitedHealth Group, are taking immediate action to help people in western Wisconsin who may be affected by the recent flooding. This includes assisting health plan participants who may need to make alternate..."/>
UnitedHealthcare and Optum Support People Affected by Floods in Western Wisconsin
Pieris Pharmaceuticals, Inc., a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform, announced that it has today presented new preclinical data demonstrating in vivo efficacy of its lead 4-1 BB- based bispecific cancer immunotherapeutic drug candidate, PRS-343, at the 2016 CRI-CIMT-AACR International Cancer Immunotherapy Conference- Translating Science into Survival, taking place in New..."/>
Pieris Pharmaceuticals Presents Positive Data for Its Lead Bispecific Drug Candidate, PRS-343, at the 2016 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
Infinity Pharmaceuticals, Inc. today announced initial clinical and new preclinical data for IPI-549, an orally administered immuno-oncology development candidate that selectively inhibits PI3K-gamma. Preliminary Phase 1 results from nine patients with advanced solid tumors show that the safety, pharmacokinetics and pharmacodynamics of IPI-549 monotherapy treatment appear favorable. Additionally, new preclinical data..."/>
Infinity Presents Initial Clinical And New Preclinical Data On IPI-549 At Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
Cigna will give it more market power, saving the insurer billions of dollars and reducing charges for customers. Department of Justice, which is seeking to stop the nation's second-largest health insurer from buying Bloomfield-based Cigna, argues that more leverage at a larger Anthem could hurt doctors and hospitals, and therefore hurt the quality of health care..."/>
Anthem Says Cigna Merger Will Cut Costs, Create Savings [The Hartford Courant]
CareDx, Inc., a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the closing of its previously announced underwritten public offering of 2,250,000 shares of its common stock at a public offering price of $4.00 per share, before deducting underwriting discounts and commissions and estimated..."/>
CareDx Announces Closing of Public Offering of Common Stock
Amgen today announced that the nomination process to submit proposals to receive an Amgen-sponsored LabCentral Golden Ticket is open for interested life-sciences and biotech startup companies in Massachusetts. LabCentral is an innovative, shared laboratory space designed as a launch pad for premier high-impact life-sciences and biotech startups. As one of LabCentral's platinum sponsors, Amgen can nominate up to two..."/>
Amgen Opens Nomination Process For LabCentral Residency
Navidea Biopharmaceuticals, Inc. today announced that its Board of Directors has appointed Michael M. Goldberg, M.D. as President and Chief Executive Officer effective September 22, 2016. The Board of Directors has also appointed Eric K. Rowinsky M.D., a Navidea board member since 2010, as Chairman of Navidea’ s Board, a position previously held by Dr."/>
Navidea Appoints Michael M. Goldberg, M.D. President and Chief Executive Officer
MyoKardia, Inc., a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it has commenced an underwritten public offering of 3,800,000 shares of its common stock. All shares of common stock will be offered by MyoKardia. In addition, MyoKardia expects to grant the underwriters a 30- day option to purchase up to an additional..."/>
MyoKardia Announces Proposed Public Offering of Common Stock

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology508 Articles
Consumer Discretionary486 Articles
Industrials298 Articles
Financials289 Articles
Health Care267 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.